Statistics for Immunogenicity and safety following a homologous booster dose of a SARSCoV2 recombinant spike protein vaccine with MatrixMTM adjuvant NVXCoV2373 versus a primary series in people living with and without HIV1 infection in South Africa A randomized cro
Total visits
views | |
---|---|
Immunogenicity and safety following a homologous booster dose of a SARSCoV2 recombinant spike protein vaccine with MatrixMTM adjuvant NVXCoV2373 versus a primary series in people living with and without HIV1 infection in South Africa A randomized cro | 1 |
Total visits per month
views | |
---|---|
November 2024 | 0 |
December 2024 | 0 |
January 2025 | 0 |
February 2025 | 0 |
March 2025 | 0 |
April 2025 | 1 |
May 2025 | 0 |
File Visits
views | |
---|---|
Journal Article.pdf | 5 |